NEPT vs NVS

Neptune Wellness Solutions Inc.

Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Neutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.